Literature DB >> 32014927

The Effect of Cold Atmospheric Plasma on the Membrane Permeability of Human Osteosarcoma Cells.

Lyubomir Haralambiev1,2, Andreas Nitsch2, Rebekka Einenkel3, Damian O Muzzio3, Nadine Gelbrich4, Martin Burchardt4, Marek Zygmunt3, Axel Ekkernkamp5,2, Matthias B Stope4, Denis Gümbel5,2.   

Abstract

BACKGROUND: Cold atmospheric plasma (CAP) has a variety of anticancer effects on different cancer cell types. In osteosarcoma (OS) cells, CAP reduces growth and motility, induces apoptosis, and alters secretion of cellular factors. The influence of CAP on membrane integrity of OS cells is unknown.
MATERIALS AND METHODS: Two different OS cell lines (U-2 OS and MNNG-HOS) were treated with CAP. Proliferation assays for cell growth after treatment was performed. Alterations in membrane permeability and the associated translocation of low molecular weight particles through the cytoplasmic membrane of OS cells after CAP treatment were shown in fluorescein diacetate (FDA) assays.
RESULTS: FDA increasingly passed the membrane after CAP treatment and this effect depended on the duration of treatment. It was also shown that after CAP treatment, FDA was able to diffuse into the cells from the outside as well as out of the cell interior. These effects were observed when CAP-treated buffer was used and therefore no direct contact between cells and CAP occurred.
CONCLUSION: The observations suggest that changes in membrane permeability and function may contribute to the antiproliferative effects of CAP. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Cell permeabilisation; cold atmospheric plasma; osteosarcoma

Mesh:

Substances:

Year:  2020        PMID: 32014927     DOI: 10.21873/anticanres.14016

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Cold Atmospheric Plasma Reduces Vessel Density and Increases Vascular Permeability and Apoptotic Cell Death in Solid Tumors.

Authors:  Philipp Kugler; Sven Becker; Christian Welz; Nadine Wiesmann; Jonas Sax; Christoph R Buhr; Markus H Thoma; Juergen Brieger; Jonas Eckrich
Journal:  Cancers (Basel)       Date:  2022-05-14       Impact factor: 6.575

2.  An Innovative Therapeutic Option for the Treatment of Skeletal Sarcomas: Elimination of Osteo- and Ewing's Sarcoma Cells Using Physical Gas Plasma.

Authors:  Josephine M Jacoby; Silas Strakeljahn; Andreas Nitsch; Sander Bekeschus; Peter Hinz; Alexander Mustea; Axel Ekkernkamp; Mladen V Tzvetkov; Lyubomir Haralambiev; Matthias B Stope
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

Review 3.  The Modulatory Effects of Non-Thermal Plasma on Seed's Morphology, Germination and Genetics-A Review.

Authors:  Livia-Ioana Leti; Ioana Cristina Gerber; Ilarion Mihaila; Paula-Maria Galan; Silvia Strajeru; Denisa-Elena Petrescu; Mirela-Mihaela Cimpeanu; Ionut Topala; Dragos-Lucian Gorgan
Journal:  Plants (Basel)       Date:  2022-08-22

Review 4.  Possible Synergies of Nanomaterial-Assisted Tissue Regeneration in Plasma Medicine: Mechanisms and Safety Concerns.

Authors:  Priyanka Shaw; Patrick Vanraes; Naresh Kumar; Annemie Bogaerts
Journal:  Nanomaterials (Basel)       Date:  2022-09-28       Impact factor: 5.719

5.  Cold Atmospheric Plasma Treatment of Chondrosarcoma Cells Affects Proliferation and Cell Membrane Permeability.

Authors:  Lyubomir Haralambiev; Andreas Nitsch; Josephine M Jacoby; Silas Strakeljahn; Sander Bekeschus; Alexander Mustea; Axel Ekkernkamp; Matthias B Stope
Journal:  Int J Mol Sci       Date:  2020-03-26       Impact factor: 5.923

6.  New Approach against Chondrosoma Cells-Cold Plasma Treatment Inhibits Cell Motility and Metabolism, and Leads to Apoptosis.

Authors:  Andreas Nitsch; Silas Strakeljahn; Josephine M Jacoby; Konrad F Sieb; Alexander Mustea; Sander Bekeschus; Axel Ekkernkamp; Matthias B Stope; Lyubomir Haralambiev
Journal:  Biomedicines       Date:  2022-03-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.